Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership
2025年1月3日 - 7:20AM
Edgar (US Regulatory)
Exhibit 99.1
Annex A
The Reporting Person currently has the following outstanding options
pursuant to the Issuer’s equity plans:
Date
of option
grant |
Number
of
shares |
Exercise
Price
Per Share |
Vesting
Schedule |
Expiration
Date |
Portion
Vested
at 12/23/2024 |
| 4/12/2022 |
7,143 |
$210 |
Vests
in four equal annual installments beginning on April 12, 2023. |
04/12/2032 |
3,572 |
| 10/26/2023 |
80,965 |
$5.75 |
Vests
in four annual installments with 20% vesting on each of October 26, 2024, 2025 and 2026 and 40% vesting on October 26, 2027. |
10/26/2033 |
16,193 |
| 12/09/2024 |
536,603
|
$0.78 |
Vests
in four annual installments with 20% vesting on each of December 9, 2025, 2026 and 2027 and 40% vesting on December 9, 2028. |
12/09/2034 |
__ |
The vesting of the unvested options described above will increase
the Reporting Person's beneficial ownership of Ordinary Shares.
Quoin Pharmaceuticals (NASDAQ:QNRX)
過去 株価チャート
から 12 2024 まで 1 2025
Quoin Pharmaceuticals (NASDAQ:QNRX)
過去 株価チャート
から 1 2024 まで 1 2025
